Opinion|Videos|March 20, 2025
Other Investigational Drug Delivery Systems in NMIBC
Experts briefly discuss investigational mitomycin delivery systems UGN-102 and UGN-103, which are being evaluated in intermediate-risk non–muscle-invasive bladder cancer (NMIBC), and share their impressions of the safety and efficacy results from the ENVISION phase 3 trial for UGN-102.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please briefly discuss investigational mitomycin delivery systems UGN-102 and UGN-103, which are being evaluated in intermediate-risk NMIBC. What are your impressions of the safety and efficacy results from the ENVISION phase 3 trial for UGN-102?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Ridwan I. Alam, MD, MPH, discusses combining PHI and MRI to predict prostate cancer risk
2
Targeting BCG resistance in high-risk NMIBC
3
FDA grants 510(k) clearance to Break Wave lithotripsy device for kidney stones
4
Practical guide to female pelvic organ–sparing radical cystectomy
5